UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...
Econostrum on MSN
DWP Benefit Boost: Could You Be Eligible for £749 a Month?
The Department for Work and Pensions (DWP) has revealed that almost 1.2 million adults across Great Britain are currently ...
Ice and heat therapy are two common treatments for back pain. Knowing when to use one over the other is important for healing ...
Once known as a disease of aging, arthritis is now surfacing in younger adults and teens. Experts warn that long hours of ...
Everyone’s experience with axSpA is different, but these real-life strategies show there are multiple ways to find relief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback